Boston Scientific earnings: Writedown pushes BSX into Q3 red
Boston Scientific says an $809 million writedown for its cardiac rhythm management unit pushed it into a loss for the 3rd quarter.
Still, excluding 1-time items, the Natick, Mass.-based medical device company managed to beat Wall Street's expectations by a penny.
BSX logged a net loss of $725 million, or 52¢ per share, on sales of $1.74 billion for the 3 months ended Sept. 30. That represents a 7.4% top-line slide.